Legal Representation
Attorney
Mark Harrison
USPTO Deadlines
Application History
21 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Aug 22, 2016 | MAB6 | O | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED | Loading... |
| Aug 22, 2016 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Jan 19, 2016 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Nov 24, 2015 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Nov 24, 2015 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Nov 4, 2015 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Oct 17, 2015 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED | Loading... |
| Oct 16, 2015 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Oct 15, 2015 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Oct 15, 2015 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Oct 15, 2015 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Oct 1, 2015 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Oct 1, 2015 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Oct 1, 2015 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Sep 24, 2015 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jul 9, 2015 | AMPX | O | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | Loading... |
| Jul 2, 2015 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Jun 22, 2015 | PARI | I | TEAS VOLUNTARY AMENDMENT RECEIVED | Loading... |
| Jun 20, 2015 | MPMK | E | NOTICE OF PSEUDO MARK E-MAILED | Loading... |
| Jun 19, 2015 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jun 19, 2015 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical and drug preparations for use in treatment of opioid overdose and addiction; Medicinal preparations for use in treatment of opioid overdose and addiction; Pharmaceutical and drug preparations for the treatment of substance use disorders, addiction, and overdose; Medicinal preparations for the treatment of substance use disorders, addiction, and overdose; Pharmaceutical preparations, namely, opioid antagonists; pharmaceutical preparations, namely, pharmaceuticals which contain the compound naloxone for the treatment of complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids
First Use Anywhere:
0
First Use in Commerce:
0
Additional Information
Pseudo Mark
NALONASE
Classification
International Classes
005